DRG Market Assessment reports

Decision Resources Group (DRG) estimates that 80% of the more than 3 million diagnosed prevalent cases of schizophrenia within our surveyed markets (i.e., United States, France, Germany, and United…

The U.S. rheumatoid arthritis (RA) market is crowded, with the availability of nine different biologics and Xeljanz, representing six distinct drug classes. With the impending entry of biosimilars…

Introduction Rheumatoid arthritis (RA) affects a significant percentage of Argentinian and Mexican populations and often requires the use of premium-priced biologics. Rheumatologists have…

Introduction Rheumatoid arthritis (RA) is a chronic disease that affects more than 1 million Brazilians and often requires the use of premium-priced therapies. The coverage of these drugs is…

Nine biologics are approved to treat rheumatoid arthritis (RA), along with an oral Jak inhibitor Xeljanz (Pfizer). Given rheumatologists’ long-standing familiarity with the safety and efficacy…

Rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are chronic and, in many cases, debilitating diseases requiring lifelong treatment. Costs associated with biologic treatment for RA…

Introduction Rheumatoid arthritis (RA) represents a lucrative market, particularly because of the entrenched positioning of biologics in the treatment algorithm. A number of RA biologics have…

Last Updated 14 December 2015 The rheumatoid arthritis (RA) therapy market has matured to the point that TNF-α inhibitors have become firmly established as first-line biological agents, leaving…

The entrenched positioning of biologics (in particular, tumor necrosis factor-alpha [TNF-alpha] inhibitors) to treat moderate-to-severe rheumatoid arthritis (RA) has generated a multi-billion-…

Through comprehensive primary research methods, the TreatmentTrends: Rheumatoid Arthritis 2015 (US) report explores the treatment dynamics among 100 U.S. rheumatologists and how these have evolved…

ChartTrends: Rheumatoid Arthritis 2015 (US) provides insight into the management and treatment of RA patients by rheumatologists based on actual patient-level data. 224 U.S. rheumatologists…

For the estimated 2 million diagnosed patients in the United States who suffer from rheumatoid arthritis (RA), there are multiple prescription therapies that are available for treating the…